Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are spectrum of rare, acute, and life-threatening delayed-type drug hypersensitivity reactions that are associated with high mortality rates. However, no therapeutic standard has been proposed for SJS/TEN. Here, we report a case of a patient diagnosed with Stevens–Johnson syndrome whose disease progression was halted by a single dose of etanercept and was treated successfully. In addition, we reviewed the literature reporting patients with SJS/TEN treated with similar regimens.

CONFLICT OF INTEREST

None reported.

Supporting Information

REFERENCES

Abe, R. (2015). Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis. The Journal of Dermatology, 42, 42–48.
10.1111/1346-8138.12674
CAS PubMed Web of Science® Google Scholar
Chong, I., & Chao, A. (2017). Stevens-Johnson syndrome/toxic epidermal necrolysis and treatment with a biologic: A case report. Permanente Journal, 21, 16–060.
PubMed Google Scholar
Didona, D., Paolino, G., Garcovich, S., Caposiena Caro, R. D., & Didona, B. (2016). Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. Journal of the European Academy of Dermatology and Venereology, 30, e83–e84.
10.1111/jdv.13330
CAS PubMed Web of Science® Google Scholar
Dodiuk-Gad, R. P., Chung, W. H., Valeyrie-Allanore, L., & Shear, N. H. (2015). Stevens-Johnson syndrome and toxic epidermal necrolysis: An update. American Journal of Clinical Dermatology, 16, 475–493.
10.1007/s40257-015-0158-0
PubMed Web of Science® Google Scholar
Famularo, G., Di, D. B., Canzona, F., Girardelli, C. R., & Cruciani, G. (2007). Etanercept for toxic epidermal necrolysis. Annals of Pharmacotherapy, 41, 1083–1084.
10.1345/aph.1K001
PubMed Web of Science® Google Scholar
Gavigan, G. M., Kanigsberg, N. D., & Ramien, M. L. (2018). Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by etanercept. Journal of Cutaneous Medicine and Surgery, 22, 514–515.
10.1177/1203475418758989
PubMed Web of Science® Google Scholar
Gubinelli, E., Canzona, F., Tonanzi, T., Raskovic, D., & Didona, B. (2009). Toxic epidermal necrolysis successfully treated with etanercept. The Journal of Dermatology, 36, 150–153.
10.1111/j.1346-8138.2009.00616.x
CAS PubMed Web of Science® Google Scholar
Lee, Y. Y., Ko, J. H., Wei, C. H., & Chung, W. H. (2013). Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient. Dermatologica Sinica, 31, 78–81.
10.1016/j.dsi.2012.06.005
Web of Science® Google Scholar
Paradisi, A., Abeni, D., Bergamo, F., Ricci, F., Didona, D., & Didona, B. (2014). Etanercept therapy for toxic epidermal necrolysis. Journal of the American Academy of Dermatology, 71, 278–283.
10.1016/j.jaad.2014.04.044
CAS PubMed Web of Science® Google Scholar
Sadighha, A. (2009). Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis/toxic epidermal necrolysis: Definition of a new model based on translational research. International Journal of Dermatology, 48, 913–914.
10.1111/j.1365-4632.2008.04020.x
CAS PubMed Web of Science® Google Scholar
Saeed, H. N., & Chodosh, J. (2016). Immunologic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis. Seminars in Ophthalmology, 31, 85–90.
10.3109/08820538.2015.1115255
PubMed Web of Science® Google Scholar
St John, J., Ratushny, V., Liu, K. J., Bach, D. Q., Badri, O., Gracey, L. E., … Kroshinsky, D. (2017). Successful use of Cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatric Dermatology, 34, 540–546.
10.1111/pde.13236
PubMed Web of Science® Google Scholar
Wang, C. W., Yang, L. Y., Chen, C. B., Ho, H. C., Hung, S. I., Yang, C. H., … the Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium. (2017). Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. Journal of Clinical Investigation, 128, 985–996.
10.1172/JCI93349
Web of Science® Google Scholar

Citing Literature

All articles

Rapid remission of Stevens–Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature

Abstract

CONFLICT OF INTEREST

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Rapid remission of Stevens–Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature

Abstract

CONFLICT OF INTEREST

Supporting Information

REFERENCES

Citing Literature

References

Related

Information